Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer

Fig. 3

MEDI3039 sensitivity is different depending on breast cancer subtypes. IC50 of MEDI3039 (a) and IC50 of GST-TRAIL (b) were obtained by GraphPad Prism Nonlinear regression analysis of multiple MTS assays with 3 days of cell culture (at least three times per cell line). c Correlation of IC50 between MEDI3039 and GST-TRAIL in 15 breast cancer cell lines. Note that BT474 and T47D were out of scale because IC50 could not be determined due to resistance to MEDI3039 and GST-TRAIL

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us